NEWS HIGHLIGHTSMedia Articles Related to Fareston (Toremifene)
Metformin Won't Aid Breast Cancer Survival in Diabetics
Source: MedicineNet Breast Specialty [2013.05.15]
Title: Metformin Won't Aid Breast Cancer Survival in Diabetics
Category: Health News
Created: 5/14/2013 6:36:00 PM
Last Editorial Review: 5/15/2013 12:00:00 AM
Angelina Jolie Has Double Mastectomy Because Of 87% Breast Cancer Risk
Source: Breast Cancer News From Medical News Today [2013.05.14]
Actress Angelina Jolie, who carries a mutation in her BRCA1 gene, announced that she has had a double mastectomy. Women who carry a BRCA1 or BRCA2 mutation have a significantly higher risk of developing breast and ovarian cancers. According to Angelina Jolie, her lifetime risk of developing breast cancer before having her breasts surgically removed was 87%...
The Older Breast Cancer Survivor: What Does She Need?
Source: Medscape Nurses Headlines [2013.05.13]
Few studies have examined the experiences and needs of women living into old age after breast cancer treatment.
Medscape Nurses
Gene Expression Profiling In Breast Cancer
Source: Breast Cancer News From Medical News Today [2013.05.13]
Predicting outcomes for cancer patients based on tumor-immune system interactions is an emerging clinical approach, and new research from Wake Forest Baptist Medical Center is advancing the field when it comes to the most deadly types of breast cancer...
Social Interaction Can Help Relieve Breast Cancer Symptoms
Source: Breast Cancer News From Medical News Today [2013.05.12]
Breast cancer patients who have lots of friends and social relationships tend to cope with the pain and other symptoms associated with the disease better than those who are more isolated, according to new research published in the journal Breast Cancer Research and Treatment. Lead author of the study Candyce H...
Published Studies Related to Fareston (Toremifene)
Toremifene decreases vertebral fractures in men younger than 80 years receiving
androgen deprivation therapy for prostate cancer. [2011]
men younger than 80 years... CONCLUSIONS: Toremifene significantly decreased new vertebral fractures in men
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. [2010.10]
PURPOSE: Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men receiving androgen deprivation therapy during a 2-year period... CONCLUSIONS: Toremifene significantly decreased the incidence of new vertebral fractures in men receiving androgen deprivation therapy for prostate cancer. It also significantly improved bone mineral density, bone turnover markers and serum lipid profiles. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. [2010.07]
OBJECTIVE: Toremifene and tamoxifen have been used for adjuvant therapy in post-menopausal patients with breast cancer in Japan. Dyslipidemias are common in post-menopausal women. However, limited data are available on the effects of these agents on lipid profiles in Japanese patients. The Japan Toremifene Cooperative Study Group has been conducting a Phase III randomized trial of post-menopausal patients with breast cancer. One of its secondary endpoints is to confirm the effects of these agents on serum lipid profiles... CONCLUSIONS: Distinct differences between two selective estrogen receptor modulators on lipids were observed. Toremifene improved lipid profiles, particularly as an enhancer of high-density lipoprotein cholesterol. To a large extent, tamoxifen improved low-density lipoprotein cholesterol levels. The impact of these improved lipid profiles on the risk of cardiovascular diseases needs further confirmation.
Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. [2010.05.15]
BACKGROUND: Fareston (toremifene) and tamoxifen, both selective estrogen receptor modulators, are therapeutically equivalent treatments for metastatic breast cancer. We hypothesized that toremifene as compared with tamoxifen given as adjuvant therapy for early stage breast cancer would result in equivalent survival with an improved side effect profile, therefore, providing superior therapeutic efficacy... CONCLUSIONS: Women treated with adjuvant hormonal therapy enjoyed excellent DFS and OS. No significant differences were found between treatment with either tamoxifen or toremifene. Treatment of HR-positive patients with either tamoxifen or toremifene is appropriate. (c) 2010 American Cancer Society.
Cardiovascular safety of degarelix: results from a 12-month, comparative,
randomized, open label, parallel group phase III trial in patients with prostate
cancer. [2010]
gonadotropin-releasing hormone antagonist... CONCLUSIONS: In men with prostate cancer degarelix and leuprolide have similar
Clinical Trials Related to Fareston (Toremifene)
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer [Terminated]
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29,
and will continue to compare combined hormonal therapy using the experimental aromatase
inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene
(FarestonŽ), to the single agent FDA-approved aromatase inhibitor letrozole (FemaraŽ) for the
treatment of advanced breast cancer. The purpose of this study is to determine whether
maximal estrogen suppression achieved via the combination of atamestane, plus toremifene
(FarestonŽ), is more effective than letrozole (FemaraŽ) in delaying the growth of breast
cancer.
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer [Terminated]
The purpose of this study is to determine whether maximal estrogen suppression achieved via
the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene
(FarestonŽ), is more effective than another approved drug, letrozole (FemaraŽ), in delaying
the growth of breast cancer, and whether the side effects of the combined hormonal therapy
are different from the side effects of letrozole.
The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia [Active, not recruiting]
The purpose of this study is to determine the effect of toremifene treatment to the MRI
findings of the breast in women suffering from premenstrual mastalgia.
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer [Not yet recruiting]
The purpose of this study is to determine whether Toremifene Citrate is effective in
reducing the risk of bone fractures in men with prostate cancer who are on Androgen
Deprivation Therapy.
Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer [Recruiting]
Reports of Suspected Fareston (Toremifene) Side Effects
Hepatic Function Abnormal (4),
White Blood Cell Count Decreased (4),
Interstitial Lung Disease (3),
Hepatitis Acute (2),
Condition Aggravated (2),
Bronchiectasis (2),
Diarrhoea (2),
Respiratory Failure (2),
Neoplasm Progression (1),
Osteomyelitis (1), more >>
|
